Abbott Laboratories (ABT) — Fair Value Analysis

Base-case fair value (P50): $93.26 · Current price: $95.39 · Verdict: Fairly Valued

The Verdict on ABT

Based on our Monte Carlo simulation, Abbott Laboratories (ABT) is currently assessed as Fairly Valued. Trading at $95.39, ABT’s current market price is -2.2% compared to its median fair value (P50) of $93.26. This narrow divergence between $95.39 and $93.26 positions ABT squarely within a reasonable valuation range, reflecting a market price closely aligned with the probabilistic intrinsic value derived from thousands of simulated forward scenarios.

How ABT stacks up against Healthcare

In the context of the Healthcare sector, ABT maintains an average quality tier, signifying a stable operational and financial health profile relative to its industry peers. This average quality tier supports the Fairly Valued verdict, as it implies no significant structural advantages or disadvantages that would warrant a substantial premium or discount from its median fair value of $93.26. The current price of $95.39 accurately reflects ABT's standing within a competitive and evolving sector, without suggesting undue market optimism or pessimism.

What this means for investors

For investors considering Abbott Laboratories, the fair valuation indicated by its $95.39 relative to a median fair value of $93.26 suggests that significant immediate upside or downside is less probable based on current fundamentals. While -2.2% indicates a slight variance, it falls within the bounds of what our model considers a balanced valuation. Investors should weigh this Fairly Valued assessment against their individual risk appetites and investment horizons. To understand the full range of potential outcomes, including detailed bear and bull case scenarios and the probability of achieving upside, sign up for a free FairCurve account.